Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 194 posts  |  Last Activity: 37 minutes ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • kadaicher1 kadaicher1 37 minutes ago Flag

    PBT2 is an antibiotic with excellent BBB penetrating ability. Zn analog the antibiotic clioquinol, but it was chosen for its attraction to metals.
    From a Tanzi interview this month
    [I also have two drugs in clinical trials. One, that stops the amyloid from aggregating, is called PBT2, from Prana Biotechnology, a company I founded in my lab. That drug aims to stop the aggregation of the amyloid in the brain so it can clear out. And then we have another drug that is just getting into clinical trials that stops the amyloid from being made, that’s called GSM, which stands for gamma-secretase modulator. So one of them basically turns off the spigot, the other unclogs the drain.]
    Of course brain damage which causes excess AB to build can be from other sources, for instance AB build is seen around traumatic brain injury. AB increase has even been noted right after lumbar puncture for no apparent reason.
    Obviously Prof Tanzi does not think PBT2 is finished as an AD treatment. Which is what Prana have stated also.

    Sentiment: Strong Buy

  • Reply to

    Amyloid beta Homeostasis

    by copper725 16 hours ago
    kadaicher1 kadaicher1 15 hours ago Flag

    It is metal homeostasis with PBT2, mainly inside the neurons. What is homeostasis of AB? Please explain. AB is produced as needed. It has an affinity to metals just a little lower than PBT2.
    No Tanzi was not in on that, but he did speak out against that direction of research, and even provided evidence that AB is a component of the brain's innate immune system.

    Sentiment: Strong Buy

  • Reply to

    Inhibiting AB Aggregation

    by tb00tb00a 16 hours ago
    kadaicher1 kadaicher1 15 hours ago Flag

    An independent opinion from Merz and the Planck Institute when they tested the MOA. [The data indicates that it may be most beneficial for neuroprotective agents such as PBT2, that can interrupt Aβ self-assembly into aggregates, to be administered to early stage patients to best maintain synaptic plasticity and function as an effective treatment for Alzheimer's Disease (AD).]

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 16 hours ago Flag

    Considering no disease modifying AD trials have succeeded, that last sentence is not something everybody here needed to read, and they were rushed in with poor P2 or failed P2 results.

    Sentiment: Strong Buy

  • Reply to

    opps! - Rudy has a new theory

    by pvretire 19 hours ago
    kadaicher1 kadaicher1 17 hours ago Flag

    Nothing new there that I can see, it was Tanzi and Moir who proposed this several years ago. Maybe the new development is that the theory is now being taken seriously.
    FYI PBT2 does not directly attack the AB system, which I think is a big advantage over MAB's.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 20 hours ago Flag

    Sounds like PBT2 is a candidate to fit right in there. That work he and Moir did was a few years before the IMAGINE and Reach2HD trials. They published it before the big monoclonal antibody failures from PFE, JNJ, ELN, LLY etc were complete. Big development dollars were wasted. Pharmas can ignore scientists like Tanzi at their own financial risk. I have seen opinion from Tanzi years back talking about multiple causes for AD. What is new here is that Tanzi has now been able to again demonstrate the amyloid effect on pathogens, this time with live human cells in a petri dish.
    Now we know AD is a reaction to various threats to the brain I see no reason to be optimistic that even an adjustable secretase inhibitor or direct removal antibody will do the job, where pathogens are concerned. An anti aggregation treatment like PBT2 will more likely fit the bill, with control through metal binding and not in any way a direct attack on the AB system, which is part of the brains immune system which may be in a fight with a pathogen.
    [The broad therapeutic potential of 8-OHQs has considerable implications because of the heterogeneous nature of neurodegenerative diseases. Brains of patients often present diverse, overlapping pathologies.](Lindquist)
    Considering his position it is not a surprise Tanzi is working on several directions of neurodegeneration research.
    [Dr. Rudolph Tanzi is a Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology at Harvard University. At the Massachusetts General Hospital (MGH), Dr. Tanzi serves as the Vice-Chair of Neurology (Research) and Director of the Genetics and Aging Research Unit, which consists of eight laboratories investigating the genetic causes of Alzheimer’s disease. ]

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 23 hours ago Flag

    The emergence of PBT434 in ther clinic will be a good addition. Looking at the chart of attraction strength in the Prana World Orphan Drug Congress presentation Prana will now have the capability of combining in a much better iron attraction with their zinc and copper ionaphore PBT2. That could be great news in HD. Reach2HD did not reduce iron as I recall.
    [Alterations in Brain Transition Metals in Huntington Disease
    An Evolving and Intricate Story
    H. Diana Rosas, MD, Y. Iris Chen, PhD, Gheorghe Doros, PhD, David H. Salat, PhD, Nan-kuei Chen, PhD, Ken K. Kwong, PhD, Ashley Bush, MD, PhD, Jonathan Fox, PhD, and Steven M. Hersch, MD, PhD
    Results
    In the basal ganglia, progressive increases in the phase evolution were found in HD, beginning in pre-manifest individuals who were far from expected onset and increasing with proximity to expected onset and thereafter. Increases in the cerebral cortex were regionally selective and present only in symptomatic HD. Increases were verified by excessive deposition of brain iron, but a complex alteration in other transition metals was found.]

    Sentiment: Strong Buy

  • Reply to

    What now?

    by copper725 May 25, 2016 7:14 AM
    kadaicher1 kadaicher1 May 25, 2016 1:02 PM Flag

    Prana have been working to get PBT2 through trials since 2005. They started the first AD P2 trials in 2006 and the results came in at the peak of the global financial crisis towards the end of 2008. The ranking analysis was published in 2009. In 2011(I think) Prana indicated they would lead to market with PBT2 in HD because much smaller trials would be required. The HD trial was a success, as the first ever HD trial in HD for PBT2 the trial primary endpoint had to be safety. A hit in a cognition endpoint was a very encouraging and will be the focus of the coming P3 registration trial. There is no drug for cognition and at a recent conference cognition was voted as the main concern amongst people with HD risk. Right now Prana are upgrading the toxicology package at the request of the FDA before a P3 is done in the USA.

    Sentiment: Strong Buy

  • Reply to

    What now?

    by copper725 May 25, 2016 7:14 AM
    kadaicher1 kadaicher1 May 25, 2016 12:44 PM Flag

    Rubbish not worth a reply.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 25, 2016 6:43 AM Flag

    I would clarify it to you but you are just a troll so why bother? Just take ACAD as an example of a company moving towards their first drug approval, and work out the value of an approved neuro drug yourself. Prana market cap $32.39m ACAD market cap $3,95B. Is that a multiple of 120, yep I believe it is.
    With that in mind, a multiple of 4 should not be out of the question once the trial to reach the point of approval is commenced.
    Keep in mind there is likely to be a concurrent Parkinsonian clinical program running and those diseases are urgent unserved orphans.

    Sentiment: Strong Buy

  • Reply to

    Some movement on the ASX

    by interestingtome May 23, 2016 10:47 PM
    kadaicher1 kadaicher1 May 24, 2016 6:27 PM Flag

    So you don't understand biotech development, but everybody knows this. FYI Prana is about average. ACADIA Pharmaceuticals Inc. was founded in 1993 and still waiting on first approved drug with a MC of $3.95B

    Sentiment: Strong Buy

  • Reply to

    Some movement on the ASX

    by interestingtome May 23, 2016 10:47 PM
    kadaicher1 kadaicher1 May 24, 2016 6:05 PM Flag

    For about the 50th time, Prana have long ago stated they would not be presenting to to he EMA till the document package is complete. You know this. Once presented, in case you are a complete moron, the EMA decision is not in any way tied to the FDA decision, and Prana have stated they would start ex USA if needed. Many companies have done that.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 24, 2016 5:59 PM Flag

    Why can you not get it through your head that I don't care if it is a new opinion. I am aware it was posted previously as well. I just like to see it out there as you bashers try to convince holders to sell at this low price. This is a prediction for Prana back on track running an HD P3 an a P1 for a parkinsonian indication. Results is a whole different situation and you know my market cap predictions on good results.

    Sentiment: Strong Buy

  • Reply to

    Some movement on the ASX

    by interestingtome May 23, 2016 10:47 PM
    kadaicher1 kadaicher1 May 24, 2016 2:00 PM Flag

    Get real copper. Data package complete will be very good news. You obviously have no idea of the age of Prana's IP. It is not old.

    Sentiment: Strong Buy

  • Reply to

    Some movement on the ASX

    by interestingtome May 23, 2016 10:47 PM
    kadaicher1 kadaicher1 May 24, 2016 12:46 PM Flag

    News maybe close.

  • kadaicher1 kadaicher1 May 24, 2016 12:45 PM Flag

    What is your point? Do you disagree with the target? I think it is very conservative.
    Prana is waiting to start a final stage trial. They have been working on the data package for some time and it is reasonable to expect a result soon. Kempler has missed his guidance completion date, but that is not unexpected.
    That price will be very conservative if there is any move to get the drug to patients through some compassionate access.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 24, 2016 2:30 AM Flag

    Looks like copper is even too lazy to check Prana's presentation which lists drugs in late development. That or he is lying.
    To make it easy, go to the pranabio web site, news items and it is right near the top just under where the Aus govt just awarded Prana A$6m for research.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 24, 2016 2:03 AM Flag

    Ask the brokers, it is their target. What do they know?

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 23, 2016 3:47 PM Flag

    For PBT2, that demonstration represents clear target engagement IMO.

    Sentiment: Strong Buy

  • That is a more than a 4x just for getting back into the final stage trial. $18.00 still represents a fairly low market cap for a company in a final stage neuro trial in HD and a clinical program starting up for the Parkinsonian orphans. With no efective options available, these could be very fast to market.

    Sentiment: Strong Buy

PRAN
3.69-0.01(-0.27%)May 26 3:53 PMEDT